Cipla's Q2FY24 Financial Performance Review

In this financial performance review, we delve into the results of Cipla for the second quarter of fiscal year 2024 and analyze key metrics, including revenue, expenses, net profit, and margin.


ParticularsQ2FY23(Y-o-Y) % changeQ1FY24(Q-o-Q) % changeQ2FY24
Total Income (₹crs.)5,95115.176,4656.026,854
Expenses (₹crs.)4,8518.435,0903.345,260
Net Profit (₹crs.)79744.9299615.961,155
Margin (%)13.393.4615.411.4516.85


Cipla reported a total income of ₹6,854 crores for Q2FY24, showcasing a substantial 6.02% increase sequentially. Moreover, the company achieved significant year-on-year revenue growth, with an impressive 15.17% rise compared to Q2FY23.


Expenses for Cipla in Q2FY24 amounted to ₹5,260 crores, representing a moderate 3.34% increase compared to the preceding quarter. On a year-on-year basis, the company's expenses grew by 8.43%, reflecting the impact of various operational factors.


The net profit of Cipla for Q2FY24 was ₹1,155 crores, demonstrating strong growth and a significant 15.96% increase compared to the preceding quarter. On a year-on-year basis, the company's net profit exhibited a remarkable 44.92% growth, highlighting efficient cost management and strong revenue generation.


Cipla's margin in Q2FY24 was 16.85%, showing steady improvement with a 1.45% increase compared to the preceding quarter, Q1FY24. Year-on-year, the company's margin exhibited a notable 3.46% growth, underlining their successful strategies and effective operations.


In conclusion, Cipla's financial performance in Q2FY24 reflects robust revenue growth, efficient expense management, and improved margins. Their ability to adapt to changing market conditions and deliver strong profits demonstrates their resilience and strategic excellence. 


Stay tuned for more detailed updates on Cipla's financial performance in the coming quarters.

Top stories

Delta Corp Q1 PAT Declines 68% YoY to Rs 22 crore in FY25

4 mins read . 13 Jul 2024 . 09:30 AM


Zydus Life Gets USFDA Nod for Heart Failure Drug

3 mins read . 13 Jul 2024 . 09:23 AM


RVNL Spurts 10% on Bagging Multiple Orders Worth Rs 390 Cr

4 mins read . 13 Jul 2024 . 09:18 AM

Related Blogs

Share Market


12 mins read . 12 Jul 2024

Ritesh Agarwal: The OYO Founder’s Success Story

  • 0 people read

Share Market


15 mins read . 08 Jul 2024

Best Oil & Gas Stocks in India

  • 0 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions